Burris, KD, Molski, TF, Xu, C, Ryan, E, Tottori, K, Kikuchi, T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther
2002; 302: 381–9.
Shapiro, DA, Renock, S, Arrington, E, Chiodo, LA, Liu, LX, Sibley, DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology
2003; 28: 1400–11.
Jordan, S, Koprivica, V, Chen, R, Tottori, K, Kikuchi, T, Altar, CA.
The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur J Pharmacol
2002; 441: 137–40.
Hirose, T, Uwahodo, Y, Yamada, S, Miwa, T, Kikuchi, T, Kitagawa, H, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol
2004; 18: 375–83.
Jordan, S, Koprivica, V, Dunn, R, Tottori, K, Kikuchi, T, Altar, CA. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol
2004; 483: 45–53.
Keck, PE Jr., Marcus, R, Tourkodimitris, S, Ali, M, Liebeskind, A, Saha, A, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry
2003; 160: 1651–8.
Sachs, G, Sanchez, R, Marcus, R, Stock, E, McQuade, R, Carson, W, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol
2006; 20: 536–46.
Keck, PE, Calabrese, JR, McQuade, RD, Carson, WH, Carlson, BX, Rollin, LM, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry
2006; 67: 626–37.
Keck, PE Jr, Calabrese, JR, McIntyre, RS, McQuade, RD, Carson, WH, Eudicone, JM, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry
2007; 68: 1480–91.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revision) (DSM–IV–TR). APA, 2000.
Young, RC, Biggs, JT, Ziegler, VE, Meyer, DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry
1978; 133: 429–35.
Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry
1979; 134: 382–9.
Spearing, MK, Port, RM, Leverich, GS, Brandt, D, Nolen, W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI–BP. Psychiatry Res
1997; 73: 159–71.
Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull
1987; 13: 261–76.
White, L, Harvey, PD, Opler, L, Lindenmayer, JP. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. Psychopathology
1997; 30: 263–74.
Leon, AC, Solomon, DA, Mueller, TI, Endicott, J, Posternak, M, Judd, LL, et al. A brief assessment of psychosocial functioning of subjects with bipolar I disorder: the LIFE–RIFT. Longitudinal Interval Follow-up Evaluation–Range Impaired Functioning Tool. J Nerv Ment Disord
2000; 188: 805–12.
Simpson, GM, Angus, JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl
1970; 212: 11–9.
Barnes, TR. A rating scale for drug-induced akathisia. Br J Psychiatry
1989; 154: 672–6.
Guy, W. Abnormal Involuntary Movement Scale (AIMS). In ECDEU Assessment Manual for Psychopharmacology: 534–7. US Department of Health, Education and Welfare, 1976.
Sachs, G, Gaulin, B, Gutierrez-Esteinou, R, McQuade, R, Pikalov, A, Pultz, J, et al. Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline. J Clin Psychiatry
2007; 68: 1377–83.
Vieta, E, Bourin, M, Sanchez, R, Marcus, R, Stock, E, McQuade, R, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania. Doubleblind, randomised, comparative 12-week trial. Br J Psychiatry
2005; 187: 235–42.
Keck, PE, Orsulak, PJ, Cutler, AJ, Sanchez, R, Torbeyns, A, Marcus, RN, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord
Tohen, M, Goldberg, JF, Gonzalez-Pinto Arrillaga, AM, Azorin, JM, Vieta, E, Hardy-Bayle, MC, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry
2003; 60: 1218–26.
Bowden, CL, Grunze, H, Mullen, J, Brecher, M, Paulsson, B, Jones, M, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry
2005; 66: 111–21.
McIntyre, RS, Brecher, M, Paulsson, B, Huizar, K, Mullen, J. Quetiapine or haloperidol as monotherapy for bipolar mania – a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol
2005; 15: 573–85.
Smulevich, AB, Khanna, S, Eerdekens, M, Karcher, K, Kramer, M, Grossman, F. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol
2005; 15: 75–84.
Vieta, E, Carne, X. The use of placebo in clinical trials on bipolar disorder: a new approach for an old debate. Psychother Psychosom
2005; 74: 10–6.
Tohen, M, Jacobs, TG, Grundy, SL, McElroy, SL, Banov, MC, Janicak, PG, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry
2000; 57: 841–9.
Nasrallah, HA, Churchill, CM, Hamdan-Allan, GA. Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia. Am J Psychiatry
1988; 145: 1455–6.
Kane, JM, Smith, JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry
1982; 39: 473–81.
McIntyre, RS, Konarski, JZ, Soczynska, JK, Wilkins, K, Panjwani, G, Bouffard, B, et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv
2006; 57: 1140–4.